FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "The FDA approval of KANJINTI is an important milestone for our biosimilars portfolio, prov...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Related Links:

Publication date: Available online 20 July 2019Source: Seminars in Cancer BiologyAuthor(s): Nancy A. Espinoza-Sánchez, Martin GötteAbstractOver the past few decades, understanding how tumor cells evade the immune system and their communication with their tumor microenvironment, has been the subject of intense investigation, with the aim of developing new cancer immunotherapies. The current therapies against cancer such as monoclonal antibodies against checkpoint inhibitors, adoptive T-cell transfer, cytokines, vaccines, and oncolytic viruses have managed to improve the clinical outcome of the patients. However,...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
DiscussionWe estimated higher risks of ALL in the offspring of women with pregestational diabetes. These results are consistent with previous findings and compatible with a role of prenatal glycaemic environment in childhood cancer aetiology.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 20 July 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Justin GreiweAbstractAs technology improves and telehealth companies continue to innovate, the ways in which physicians can provide care for their patients is constantly expanding. Providing quality healthcare is no longer constrained by local commutes and a brick and mortar footprint, but instead can be provided at a local, regional and national level in ways that were not feasible in the past. The possibilities are endless as we enter a brave new world where medicine and technology meet. But what e...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionOver 60% of Medicare patients with asthma continued and were adherent to omalizumab over 12-month follow-up. Patient age, LIS status, and the numbers of evaluation and management physician visits were among factors associated with treatment adherence and discontinuation.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 20 July 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Ashlynn L.Z. Lee, Chuan Yang, Shujun Gao, James L. Hedrick, Yi Yan YangAbstractProlonged vaccine release enables gradual immunostimulation, providing long-term immunity. Herein, Vitamin E- PEG-Vitamin E triblock ‘ABA’ hydrogel, which is formed through physical cross-linking of flower-shaped micelles and can reside in vivo for>17 weeks, was employed for delivery of cancer preventive vaccines to provide sustained anticancer immunity. Mice vaccinated with hydrogel formulations produced a sign...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 20 July 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Samaneh Kabirian-Dehkordi, Mounira Chalabi-Dchar, Hichem C Mertani, Dominique Le Guellec, Bernard Verrier, Jean-Jacques Diaz, Masoud A. Mehrgardi, Philippe BouvetAbstractG-rich oligonucleotide, AS1411, has been shown to interact with nucleolin and to inhibit cancer cell proliferation and tumor growth. This antiproliferative action is increased when AS1411 is conjugated to different types of nanoparticles. However, the molecular mechanisms are not known. In this work, we show in several cell lines that optimiz...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Publication date: Available online 20 July 2019Source: NeurocomputingAuthor(s): Yan Li, Lu Wang, Jiayu Zhou, Jieping YeAbstractThere are many major diseases that remain incurable, such as cancer and Alzheimer’s disease (AD). Therefore, the prevention for these diseases has more impact than diagnosis and treatment. Survival analysis aims at predicting the time of occurrence of specific events of interest. It can be used to identify patients of high risk, which helps healthcare system effectively allocate limited medical resources. In many real-world applications, such as healthcare analysis, a lot of datasets are coll...
Source: Neurocomputing - Category: Neuroscience Source Type: research
ConclusionsAt-risk smokers in Virginia, particularly those living in rural areas with high smoking rates, do not have adequate recommended LDCT coverage. More screening centers are needed to care for the high number of rural smokers at risk for lung cancer.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
In this study, we evaluated whether the combination of focused ultrasound (FUS) and microbubbles can improve adoptively NK-92MI cell infiltration into ovarian tumors through biodistribution, immunofluorescence, and flow cytometry. The treatment effects of using this strategy twice a week were explored. The potential molecular mechanism of FUS assisting NK cell therapy was also initially explored through evaluating the expression of ICAM1 and CX3CL1 by qRT-PCR. Our results indicated that FUS and microbubbles can improve NK-92MI cells’ infiltration into tumors, and the combination of FUS and NK-92MI cells had a better ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Adenocarcinoma | Allergy | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Pharmaceuticals